Featured content
Reproducible organoids start with reliable cytokines
The right signals can make or break an organoid model. From growth and differentiation to downstream drug testing, cytokines and growth factors are critical to creating cultures researchers can rely on.
ArticleFinding drug targets through the noise of complex disease
The strongest disease signal may not point to the best drug target. AI could help researchers identify what matters within complex biological networks.
ArticleFaster, scalable biologics stability testing without sacrificing data quality
Stability problems can derail promising biologics late in development. Bringing high-throughput testing earlier into discovery could help researchers identify risks before they become costly failures.
InterviewA sceptical guide to AI agents in drug discovery
AI agents promise to transform drug discovery, but where do they really add value? Dr Eric Ma examines search, model choice, vendor lock-in and why scientific expertise matters more than ever.
News
NewsMLY2 and MLY8 compounds show promise as ulcerative colitis treatment candidates
Two experimental compounds derived from a phase II metabolite have demonstrated improved anti-inflammatory activity in preclinical models of ulcerative colitis.
NewsDisrupting cell-wall transport could expose weakness in resistant bacteria
Researchers have identified a weakness in antibiotic-resistant bacteria that could help restore susceptibility to existing treatments by disrupting a lipid carrier essential for bacterial cell-wall synthesis.
NewsResearchers solve 30-year mystery of key inflammatory enzyme gene
A gene responsible for producing a critical enzyme in inflammatory signalling has been identified after more than 30 years, with findings suggesting the pathway acts as both an immune alarm and a cellular shield with implications for cancer, IBD and asthma.
NewsBacterial microrobot platform achieves 82 percent tumour inhibition in bladder cancer
A hybrid microrobotic platform combining living bacteria, nanoparticles and targeted chemotherapy has achieved 82.4 percent tumour inhibition in preclinical bladder cancer models.
From our partners
Webinar
From antibody discovery to development: long-read sequencing in practice
As sequencing continues to grow in importance across biotherapeutic discovery and development, where can it make the biggest impact and how can fragmented workflows be overcome?
Webinar
What it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
Opinion and interviews
A sceptical guide to AI agents in drug discovery
AI agents promise to transform drug discovery, but where do they really add value? Dr Eric Ma examines search, model choice, vendor lock-in and why scientific expertise matters more than ever.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Webinar
From antibody discovery to development: long-read sequencing in practice
As sequencing continues to grow in importance across biotherapeutic discovery and development, where can it make the biggest impact and how can fragmented workflows be overcome?
Webinar
Mapping the prostate tumour microenvironment with spatial proteomics
As spatial proteomics advances, how can researchers find the complex biology of the prostate tumour microenvironment while preserving spatial context? Hear experts from the University of Surrey share their approach.
Webinar
Cracking cell dynamics with single-cell proteomics and CRISPR
What can pooled CRISPR screening and protein‑level readouts reveal that transcriptomics alone can’t? Explore how single‑cell genomic perturbations, intracellular protein measurements and surface‑protein profiling expose signalling pathways and clarify antibody specificity.
Webinar
What it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
Webinar
VLPs as serological tools for diagnostics and vaccine development
What makes VLPs so useful in diagnostics and vaccine development? Explore their manufacture, serological applications and use in capturing neutralising antibodies.
Webinar
From vial to viable: best practices for culturing organoids
Poor recovery, inconsistent growth and changes in morphology can affect organoid research. How much experimental variability starts with the culture itself?
From antibody discovery to development: long-read sequencing in practice
Mapping the prostate tumour microenvironment with spatial proteomics
Cracking cell dynamics with single-cell proteomics and CRISPR
What it really takes to turn cancer discoveries into new therapies
VLPs as serological tools for diagnostics and vaccine development
From vial to viable: best practices for culturing organoids
On-demand Webinars
- Previous
- Next
